Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study
Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). The licence grants Protox exclusive worldwide rights to commercialize antibody targeted PORxin(TM) (formerly known as Aerolysin) for the treatment of non-small cell lung cancer (NSCLC). The financial terms of the agreement include an upfront fee as well as milestone and royalty payments. Protox had earlier reported the exercise of an option agreement on April 5, 2005.
The Company also announced that it has initiated a preliminary non-small cell lung cancer study with PORxin(TM) antibody fusion constructs at the BC Cancer Agency. As reported earlier, this lung cancer project has received a financial contribution of up to $340,000 from the National Research Council (NRC) Industrial Research Assistance Program (IRAP).
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.